Mitsubishi Tanabe Launches Take Over Bid For Generics Maker Choseido Pharmaceutical
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharma announced May 7 it will acquire over 50 percent stake of Tokushima-based generic drugmaker Choseido Pharmaceutical. The move is believed to strengthen Mitsubishi Tanabe's position in the generics market, generic product lineup and allows Choseido to utilize Mitsubishi Tanabe's marketing and distribution channels. Mitsubishi Tanabe is in ongoing conversations with Choseido about acquiring additional shares. (Click here for more - Japanese language
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.